Icosapent Ethyl
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Icosapent Ethyl: From Undisclosed Original Indication to Predicted Hemoglobinopathy
One-Sentence Summary
The original indication for Icosapent Ethyl is not recorded in this evidence pack (no licensed products or approved indication text available), so its established therapeutic use cannot be confirmed from the current data. The TxGNN model predicts it may be effective for Hemoglobinopathy (specifically sickle cell disease-related pathology), with 0 clinical trials and 1 preclinical publication currently supporting this direction. Given the absence of clinical trial data, market authorization, and safety/MOA information, this remains an early-stage, model-driven hypothesis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no license/indication data in evidence pack) |
| Predicted New Indication | Hemoglobinopathy |
| TxGNN Prediction Score | 99.09% |
| Evidence Level | L4 |
| Norway Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for Icosapent Ethyl is not available in this evidence pack (data gap). Based on its INN, Icosapent Ethyl is the ethyl ester of eicosapentaenoic acid (EPA), an omega-3 fatty acid — a class known for anti-inflammatory and pro-resolving lipid mediator activity.
The one supporting publication describes Epeleuton, a synthetic omega-3 fatty acid, reducing hypoxia/reperfusion-induced inflammatory vasculopathy in a mouse model of sickle cell disease — a hemoglobinopathy. Since Icosapent Ethyl belongs to the same chemical class (omega-3 fatty acid ethyl ester), there is a plausible mechanistic rationale that it could similarly modulate the inflammatory vasculopathy underlying sickle cell disease and related hemoglobinopathies. However, this link is drawn from a structurally analogous compound rather than direct evidence on Icosapent Ethyl itself, and should be treated as hypothesis-generating only.
Without confirmed original indication or MOA data for Icosapent Ethyl, the original indication–new indication relationship cannot be formally established at this time.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38105727 | 2024 | Preclinical (mouse model) | Haematologica | Epeleuton, a synthetic ω-3 fatty acid structurally related to Icosapent Ethyl's class, reduced hypoxia/reperfusion-driven inflammatory vasculopathy in a sickle cell disease mouse model, suggesting pro-resolving lipid mediators may target inflammatory pathways in hemoglobinopathies |
Norway Market Information
No authorization records available — Icosapent Ethyl is currently not marketed and has 0 registered licenses.
Safety Considerations
Please refer to the package insert for safety information.
(Note: key warnings, contraindications, and drug interaction data were not available in this evidence pack — flagged as a Blocking data gap for TFDA/regulatory warning information.)
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a single preclinical study of a structurally related (not identical) compound, with no clinical trials, no MOA confirmation, and no market authorization for Icosapent Ethyl itself. Combined with a Blocking data gap on regulatory safety warnings, there is insufficient evidence to proceed.
To proceed, the following is needed:
- TFDA/regulatory package insert data (warnings, contraindications) — currently Blocking
- Confirmed mechanism of action (MOA) for Icosapent Ethyl
- Confirmed original indication and licensing status
- Direct (not analog-based) preclinical or clinical evidence of Icosapent Ethyl in hemoglobinopathy/sickle cell disease
- Drug-drug interaction data
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.